About Us » History
Epitopix began as the laboratory service division of Willmar Poultry Company (WPC). In 2009, WPC merged with its affiliate Ag Forte LLC, and the combined company is now the largest turkey breeder and hatchery company in the United States.
During the 1980s, WPC began to seek innovative ways to improve the health of its turkey breeding stock. In order to combat Salmonella, E. coli, Pasturella (fowl cholera), and Hemorrhagic Enteritis virus, WPC created and licensed a vaccine laboratory with the USDA, and selected a premier team of scientists to pioneer novel vaccine technology. This team pursued a single vaccination that would prevent as many as 30 different serotypes of Salmonella commonly found in the production of poultry and livestock.
Through many years of research, the team developed ground-breaking technology in the form of Siderophore Receptor and Porin (SRP®) vaccines. This revolutionary vaccine process immunizes against bacterial infections utilizing a cell-free purified extract of Siderophore Receptor and Porin proteins. By 1997, vaccine made from the combined SRP® of Salmonella, E. coli, and P. multocida was in widespread use across the WPC breeder operations in Minnesota.
Epitopix, LLC formed in 2002 to commercialize SRP® Technology and to discover new vaccine technologies that improve animal health and human food safety. Discovery and development continues today to bring novel vaccine products to additional markets including livestock, poultry, and companion animals. Epitopix owns intellectual property rights to all of its discoveries and has out-licensed SRP® Technology development rights for human medical applications to Syntiron, LLC.
In 2010, Epitopix announced an agreement granting global licensing rights for its E. coli vaccine to Zoetis. In 2011, licensing rights to the Epitopix Salmonella Newport vaccine came under the Zoetis agreement. Together, Epitopix and Zoetis will continue efficacy and potency studies to achieve a full USDA license for both products.